{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T21:19:41Z","timestamp":1793481581844,"version":"4.5.0"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T00:00:00Z","timestamp":1674432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004913","name":"Universit\u00e0 degli Studi di Palermo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004913","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose of Review<\/jats:title>\n                <jats:p>Apolipoprotein C-III (ApoC-III) is a widely known player in triglyceride metabolism, and it has been recently recognized as a polyhedric factor which may regulate several pathways beyond lipid metabolism by influencing cardiovascular, metabolic, and neurological disease risk. This review summarizes the different functions of ApoC-III and underlines the recent findings related to its multifaceted pathophysiological role.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Recent Findings<\/jats:title>\n                <jats:p>The role of ApoC-III has been implicated in HDL metabolism and in the development of atherosclerosis, inflammation, and ER stress in endothelial cells. ApoC-III has been recently considered an important player in insulin resistance mechanisms, lipodystrophy, diabetic dyslipidemia, and postprandial hypertriglyceridemia (PPT). The emerging evidence of the involvement of ApoC-III in the in the pathogenesis of Alzheimer\u2019s disease open the way to further study if modification of ApoC-III level slows disease progression. Furthermore, ApoC-III is clearly linked to cardiovascular disease (CVD) risk, and progression of coronary artery disease (CAD) as well as the calcification of aortic valve and recent clinical trials has pointed out the inhibition of ApoC-III as a promising approach to manage hypertriglyceridemia and prevent CVD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Summary<\/jats:title>\n                <jats:p>Several evidences highlight the role of ApoC-III not only in triglyceride metabolism but also in several cardio-metabolic pathways. Results from recent clinical trials underline that the inhibition of ApoC-III is a promising therapeutical strategy for the management of severe hypertriglyceridemia and in CVD prevention.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11883-023-01080-8","type":"journal-article","created":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T08:02:49Z","timestamp":1674460969000},"page":"67-76","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":79,"title":["APOC-III: a Gatekeeper in Controlling Triglyceride Metabolism"],"prefix":"10.1007","volume":"25","author":[{"given":"Antonina","family":"Giammanco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Spina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo B.","family":"Cefal\u00f9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3558-9209","authenticated-orcid":false,"given":"Maurizio","family":"Averna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,23]]},"reference":[{"key":"1080_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154395","volume":"113","author":"L D\u2019Erasmo","year":"2020","unstructured":"D\u2019Erasmo L, Di Costanzo A, Gallo A, Bruckert E, Arca M. ApoCIII: a multifaceted protein in cardiometabolic disease. Metabolism. 2020;113: 154395.","journal-title":"Metabolism"},{"issue":"2","key":"1080_CR2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/01.mol.0000162320.54795.68","volume":"16","author":"CQ Lai","year":"2005","unstructured":"Lai CQ, Parnell LD, Ordovas JM, Karathanasis SK. The APOA1\/C3\/A4\/A5 gene cluster, lipid metabolism and cardiovascular disease risk. Curr Opin Lipidol. 2005;16(2):153\u201366.","journal-title":"Curr Opin Lipidol"},{"issue":"1","key":"1080_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0079-6107(03)00028-2","volume":"83","author":"VM Bolanos-Garcia","year":"2003","unstructured":"Bolanos-Garcia VM, Miguel RN. On the structure and function of apolipoproteins: more than a family of lipid-binding proteins. Prog Biophys Mol Biol. 2003;83(1):47\u201368.","journal-title":"Prog Biophys Mol Biol"},{"key":"1080_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jprot.2021.104398","volume":"251","author":"M Rodr\u00edguez","year":"2022","unstructured":"Rodr\u00edguez M, Rehues P, Iranzo V, Mora J, Balsells C, Guardiola M, et al. Distribution of seven ApoC-III glycoforms in plasma, VLDL, IDL, LDL and HDL of healthy subjects. J Proteomics. 2022;251: 104398.","journal-title":"J Proteomics"},{"key":"1080_CR5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1161\/ATVBAHA.109.197830","volume":"30","author":"CO Mendivil","year":"2010","unstructured":"Mendivil CO, Zheng C, Furtado J, Lel J, Sacks FM. Metabolism of very-low-density lipoprotein and low-density lipoprotein containing apolipoprotein C-III and not other small apolipoproteins. Arterioscler Thromb Vasc Biol. 2010;30:239\u201345.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1080_CR6","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.bbalip.2014.03.013","volume":"1841","author":"S Kersten","year":"2014","unstructured":"Kersten S. Physiological regulation of lipoprotein lipase. Biochim Biophys Acta. 2014;1841:919\u201333.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"1080_CR7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.jacl.2016.12.009","volume":"11","author":"S Mendoza","year":"2017","unstructured":"Mendoza S, Trenchevska O, King SM, Nelson RW, Nedelkov D, Krauss RM, Yassine HN. Changes in low-density lipoprotein size phenotypes associate with changes in apolipoprotein C-III glycoforms after dietary interventions. J Clin Lipidol. 2017;11(1):224-233.e2.","journal-title":"J Clin Lipidol"},{"issue":"8","key":"1080_CR8","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1172\/JCI86610","volume":"126","author":"PLS Gordts","year":"2016","unstructured":"Gordts PLS, Nock R, Son NH, Ramms B, Lew I, Gonzales JC, Thacker BE, Basu D, Lee RG, Mullick AE, Graham MJ, Goldberg IJ, Crooke RM, Witztum JL, Esko JD. ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors. J Clin Invest. 2016;126(8):2855\u201366.","journal-title":"J Clin Invest"},{"issue":"10","key":"1080_CR9","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1016\/S0022-2275(20)32211-2","volume":"42","author":"MC Jong","year":"2001","unstructured":"Jong MC, Rensen PC, Dahlmans VE, van der Boom H, van Berkel TJ, Havekes LM. Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice. J Lipid Res. 2001;42(10):1578\u201385.","journal-title":"J Lipid Res"},{"issue":"11","key":"1080_CR10","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1161\/CIRCRESAHA.111.300367","volume":"112","author":"MJ Graham","year":"2013","unstructured":"Graham MJ, Lee RG, Bell TA, Fu W, Mullick AE, Alexander VJ, et al. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ Res. 2013;112(11):1479\u201390.","journal-title":"Circ Res"},{"issue":"4","key":"1080_CR11","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1515\/hsz-2020-0288","volume":"402","author":"A Yamazaki","year":"2021","unstructured":"Yamazaki A, Ohkawa R, Yamagata Y, Horiuchi Y, Lai SJ, Kameda T, et al. Apolipoprotein C-II and C-III preferably transfer to both high-density lipoprotein (HDL)2 and the larger HDL3 from very low-density lipoprotein (VLDL). Biol Chem. 2021;402(4):439\u201349.","journal-title":"Biol Chem"},{"issue":"1","key":"1080_CR12","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/0021-9150(95)05791-9","volume":"122","author":"E Koren","year":"1996","unstructured":"Koren E, Corder C, Mueller G, Centurion H, Hallum G, Fesmire J, et al. Triglyceride enriched lipoprotein particles correlate with the severity of coronary artery disease. Atherosclerosis. 1996;122(1):105\u201315.","journal-title":"Atherosclerosis"},{"key":"1080_CR13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11883-016-0614-1","volume":"18","author":"MR Taskinen","year":"2016","unstructured":"Taskinen MR, Boren J. Why Is Apolipoprotein CIII emerging as a novel therapeutic target to reduce the burden of cardiovascular disease? Curr Atheroscler Rep. 2016;18:59.","journal-title":"Curr Atheroscler Rep"},{"key":"1080_CR14","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/MOL.0000000000000679","volume":"31","author":"LF Reeskamp","year":"2020","unstructured":"Reeskamp LF, Tromp TR, Stroes ESG. The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease? Curr Opin Lipidol. 2020;31:140\u20136.","journal-title":"Curr Opin Lipidol"},{"issue":"6","key":"1080_CR15","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.jacl.2018.08.010","volume":"12","author":"JC van Capelleveen","year":"2018","unstructured":"van Capelleveen JC, Lee SR, Verbeek R, Kastelein JJP, Wareham NJ, Stroes ESG, et al. Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: the EPIC-Norfolk prospective population study. J Clin Lipidol. 2018;12(6):1493\u2013501.","journal-title":"J Clin Lipidol"},{"key":"1080_CR16","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1126\/science.1161524","volume":"322","author":"TI Pollin","year":"2008","unstructured":"Pollin TI, Damcott CM, Shen H, Ott SH, Shelton J, Horenstein RB, et al. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science. 2008;322:1702\u20135.","journal-title":"Science"},{"key":"1080_CR17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1308027","volume":"371","author":"AB J\u00f8rgensen","year":"2014","unstructured":"J\u00f8rgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybj\u00e6rg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371:32\u201341.","journal-title":"N Engl J Med"},{"key":"1080_CR18","doi-asserted-by":"crossref","unstructured":"HDL Working Group of the Exome Sequencing Project NHL Crosby J, Peloso GM, Auer PL, et al. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371:22\u201331.","DOI":"10.1056\/NEJMoa1307095"},{"issue":"9","key":"1080_CR19","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/nrcardio.2014.99","volume":"11","author":"GT Genetics","year":"2014","unstructured":"Genetics GT. APOC3 mutations lower CVD risk. Nat Rev Cardiol. 2014;11(9):496.","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"1080_CR20","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1161\/CIRCGENETICS.113.000369","volume":"7","author":"DC Crawford","year":"2014","unstructured":"Crawford DC, Dumitrescu L, Goodloe R, Brown-Gentry K, Boston J, McClellan B Jr, et al. Rare variant APOC3 R19X is associated with cardio-protective profiles in a diverse population-based survey as part of the epidemiologic architecture for genes linked to environment (EAGLE) study. Circ Cardiovasc Genet. 2014;7(6):848\u201353.","journal-title":"Circ Cardiovasc Genet"},{"issue":"1","key":"1080_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1161\/ATVBAHA.118.311476","volume":"39","author":"G Reyes-Soffer","year":"2019","unstructured":"Reyes-Soffer G, Sztalryd C, Horenstein RB, Holleran S, Matveyenko A, Thomas T, et al. Effects of APOC3 heterozygous deficiency on plasma lipid and lipoprotein metabolism. Arterioscler Thromb Vasc Biol. 2019;39(1):63\u201372.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1080_CR22","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1016\/j.jacc.2015.08.866","volume":"66","author":"P Natarajan","year":"2015","unstructured":"Natarajan P, Kohli P, Baber U, Nguyen KDH, Sartori S, Reilly DF, et al. Association of APOC3 loss-of-function mutations with plasma lipids and subclinical atherosclerosis: the multi-ethnic bioimage study. J Am Coll Cardiol. 2015;66:2053\u20135.","journal-title":"J Am Coll Cardiol"},{"key":"1080_CR23","doi-asserted-by":"crossref","unstructured":"The TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute. Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med. 2014;371(1): 22\u201331.","DOI":"10.1056\/NEJMoa1307095"},{"key":"1080_CR24","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1161\/ATVBAHA.117.310473","volume":"38","author":"AB Wulff","year":"2018","unstructured":"Wulff AB, Nordestgaard BG, Tybj\u00e6rg-Hansen A. APOC3 Loss-of-function mutations, remnant cholesterol, low-density lipoprotein cholesterol, and cardiovascular risk mediation- and meta-analyses of 137 895 individuals. Arterioscler Thromb Vasc Biol. 2018;38:660\u20138.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"1080_CR25","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.cmet.2014.08.007","volume":"20","author":"JC Cohen","year":"2014","unstructured":"Cohen JC, Stender S, Hobbs HH. APOC3, coronary disease, and complexities of Mendelian randomization. Cell Metab. 2014;20(3):387\u20139.","journal-title":"Cell Metab"},{"key":"1080_CR26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.atherosclerosis.2020.08.017","volume":"311","author":"G Silbernagel","year":"2020","unstructured":"Silbernagel G, Scharnagl H, Kleber ME, Hoffmann MM, Delgado G, Stojakovic T, et al. Common APOC3 variants are associated with circulating ApoC-III and VLDL cholesterol but not with total apolipoprotein B and coronary artery disease. Atherosclerosis. 2020;311:84\u201390.","journal-title":"Atherosclerosis"},{"issue":"1","key":"1080_CR27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12944-021-01531-8","volume":"20","author":"S Goyal","year":"2021","unstructured":"Goyal S, Tanigawa Y, Zhang W, Chai JF, Almeida M, Sim X, et al. APOC3 genetic variation, serum triglycerides, and risk of coronary artery disease in Asian Indians, Europeans, and other ethnic groups. Lipids Health Dis. 2021;20(1):113.","journal-title":"Lipids Health Dis"},{"issue":"1","key":"1080_CR28","doi-asserted-by":"publisher","first-page":"36","DOI":"10.14336\/AD.2015.0709","volume":"7","author":"JZ Zhang","year":"2016","unstructured":"Zhang JZ, Xie X, Ma YT, Zheng YY, Yang YN, Li XM, et al. Association between apolipoprotein C-III gene polymorphisms and coronary heart disease: a meta-analysis. Aging Dis. 2016;7(1):36\u201344.","journal-title":"Aging Dis"},{"issue":"1","key":"1080_CR29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"key":"1080_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cca.2018.12.014","volume":"490","author":"H Tada","year":"2019","unstructured":"Tada H, Nohara A, Inazu A, Mabuchi H, Kawashiri MA. Remnant lipoproteins and atherosclerotic cardiovascular disease. Clin Chim Acta. 2019;490:1\u20135.","journal-title":"Clin Chim Acta"},{"issue":"3","key":"1080_CR31","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/MOL.0000000000000682","volume":"31","author":"CA Aguilar Salinas","year":"2020","unstructured":"Aguilar Salinas CA, Chapman MJ. Remnant lipoproteins: are they equal to or more atherogenic than LDL? Rev Curr Opin Lipidol. 2020;31(3):132\u20139.","journal-title":"Rev Curr Opin Lipidol"},{"key":"1080_CR32","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.cca.2011.04.018","volume":"412","author":"K Nakajima","year":"2011","unstructured":"Nakajima K, Nakano T, Tokita Y, Nagamine T, Inazu A, Kobayashi J, et al. Postprandial lipoprotein metabolism: VLDL vs chylomicrons. Clin Chim Acta. 2011;412:1306\u201318.","journal-title":"Clin Chim Acta"},{"key":"1080_CR33","doi-asserted-by":"publisher","first-page":"95","DOI":"10.5551\/jat.RV16003","volume":"24","author":"D Masuda","year":"2017","unstructured":"Masuda D, Yamashita S. Postprandial hyperlipidemia and remnant lipoproteins. J Atheroscler Thromb. 2017;24:95\u2013109.","journal-title":"J Atheroscler Thromb"},{"issue":"6","key":"1080_CR34","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/s41591-020-0934-0","volume":"26","author":"SE Berry","year":"2020","unstructured":"Berry SE, Valdes AM, Drew DA, Asnicar F, Mazidi M, Wolf J, et al. Human postprandial responses to food and potential for precision nutrition. Nat Med. 2020;26(6):964\u201373.","journal-title":"Nat Med"},{"key":"1080_CR35","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1185\/03007995.2014.909394","volume":"30","author":"A Pirillo","year":"2014","unstructured":"Pirillo A, Norata GD, Catapano AL. Postprandial lipemia as a cardiometabolic risk factor. Curr Med Res Opin. 2014;30:1489\u2013503.","journal-title":"Curr Med Res Opin"},{"key":"1080_CR36","doi-asserted-by":"crossref","unstructured":"\u2022 Ginsberg HN, Packard CJ, Chapman MJ, Bor\u00e9n J, Aguilar-Salinas CA, Averna M, et al. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society. Eur Heart J. 2021;42:4791\u20134806. This consensus critically assesses current understanding of the structure, function, and metabolism of TRLs and their pathophysiological role in atherosclerotic cardiovascular disease (ASCVD).","DOI":"10.1093\/eurheartj\/ehab551"},{"key":"1080_CR37","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","volume":"118","author":"BG Nordestgaard","year":"2016","unstructured":"Nordestgaard BG. New insights from epidemiology, genetics, and biology. Circ Res. 2016;118:547\u201363.","journal-title":"Circ Res"},{"issue":"2","key":"1080_CR38","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.atherosclerosis.2006.09.015","volume":"193","author":"GD Norata","year":"2007","unstructured":"Norata GD, Grigore L, Raselli S, Redaelli L, Hamsten A, Maggi F, et al. Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies. Atherosclerosis. 2007;193(2):321\u20137.","journal-title":"Atherosclerosis"},{"issue":"1\u20132","key":"1080_CR39","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.cell.2017.12.013","volume":"172","author":"A Christ","year":"2018","unstructured":"Christ A, G\u00fcnther P, Lauterbach MAR, Duewell P, Biswas D, Pelka K, et al. Western diet triggers NLRP3-dependent innate immune reprogramming. Cell. 2018;172(1\u20132):162-175.e14.","journal-title":"Cell"},{"key":"1080_CR40","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","volume":"317","author":"D Gaudet","year":"2014","unstructured":"Gaudet D, Brisson D, Tremblay K, Alexander VJ, Singleton W, Hughes SG, et al. Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med. 2014;317:2200\u20136.","journal-title":"N Engl J Med"},{"key":"1080_CR41","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1097\/MOL.0000000000000146","volume":"26","author":"FM Sacks","year":"2015","unstructured":"Sacks FM. The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia. Curr Opin Lipidol. 2015;26:56\u201363.","journal-title":"Curr Opin Lipidol"},{"key":"1080_CR42","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1161\/CIRCULATIONAHA.109.875807","volume":"121","author":"C Zheng","year":"2010","unstructured":"Zheng C, Khoo C, Furtado J, Sacks FM. Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype. Circulation. 2010;121:1722\u201334.","journal-title":"Circulation"},{"key":"1080_CR43","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1161\/ATVBAHA.108.169383","volume":"28","author":"M Pavlic","year":"2008","unstructured":"Pavlic M, Val\u00e9ro R, Duez H, Xiao C, Szeto L, Patterson BW, et al. Triglyceride-rich lipoprotein-associated apolipoprotein C-III production is stimulated by plasma free fatty acids in humans. Arterioscler Thromb Vasc Biol. 2008;28:1660\u20135.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1080_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.646185","volume":"12","author":"Y Guan","year":"2021","unstructured":"Guan Y, Hou X, Tian P, Ren L, Tang Y, Song A, et al. Elevated levels of apolipoprotein CIII increase the risk of postprandial hypertriglyceridemia. Front Endocrinol. 2021;12: 646185.","journal-title":"Front Endocrinol"},{"key":"1080_CR45","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Katzmann JL, Werner CM, Stojakovic T, M\u00e4rz W, Scharnagl H, Laufs U. Apolipoprotein CIII predicts cardiovascular events in patients with coronary artery disease: a prospective observational study. Lipids Health Dis. 2020;19:116. This study emphasizes the hypothesis that lowering apoC-III reduces residual cardiovascular risk.","DOI":"10.1186\/s12944-020-01293-9"},{"key":"1080_CR46","doi-asserted-by":"publisher","first-page":"6","DOI":"10.5551\/jat.E607","volume":"16","author":"A Kawakami","year":"2009","unstructured":"Kawakami A, Yoshida M. Apolipoprotein CIII links dyslipidemia with atherosclerosis. J Atheroscler Thromb. 2009;16:6\u201311.","journal-title":"J Atheroscler Thromb"},{"issue":"1","key":"1080_CR47","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1308027","volume":"371","author":"AB Jorgensen","year":"2014","unstructured":"Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG, Tybj\u00e6rg-Hansen A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. N Engl J Med. 2014;371(1):32\u201341.","journal-title":"N Engl J Med"},{"issue":"4","key":"1080_CR48","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.98045","volume":"3","author":"AM Morton","year":"2018","unstructured":"Morton AM, Koch M, Mendivil CO, Furtado JD, Tj\u00f8nneland A, Overvad K, et al. Apolipoproteins E and CIII interact to regulate HDL metabolism and coronary heart disease risk. JCI Insight. 2018;3(4): e98045.","journal-title":"JCI Insight"},{"issue":"13","key":"1080_CR49","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1161\/CIRCULATIONAHA.117.031276","volume":"137","author":"MK Jensen","year":"2018","unstructured":"Jensen MK, Aroner SA, Mukamal KJ, Furtado JD, Post WS, Tsai MY, et al. High-density lipoprotein subspecies defined by presence of apolipoprotein C-III and incident coronary heart disease in four cohorts. Circulation. 2018;137(13):1364\u201373.","journal-title":"Circulation"},{"issue":"3","key":"1080_CR50","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2337\/diabetes.52.3.803","volume":"52","author":"GF Watt","year":"2003","unstructured":"Watt GF, Barrett PHR, Ji J, Serone AP, Chan DK, Croft KD, et al. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome. Diabetes. 2003;52(3):803\u201311.","journal-title":"Diabetes"},{"key":"1080_CR51","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1111\/jcmm.16244","volume":"25","author":"AB Braiek","year":"2021","unstructured":"Braiek AB, Chahed H, Dumont F, Abdelhak F, Hichem D, Gamra H, et al. Identification of biomarker panels as predictors of severity in coronary artery disease. J Cell Mol Med. 2021;25:1518\u201330.","journal-title":"J Cell Mol Med"},{"issue":"5","key":"1080_CR52","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1161\/CIRCULATIONAHA.105.591743","volume":"113","author":"A Kawakami","year":"2006","unstructured":"Kawakami A, Aikawa M, Libby P, Alcaide P, Luscinskas FW, Sacks FM. Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human monocytic cells to endothelial cells. Circulation. 2006;113(5):691\u2013700.","journal-title":"Circulation"},{"issue":"7","key":"1080_CR53","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1161\/CIRCULATIONAHA.106.622514","volume":"114","author":"A Kawakami","year":"2006","unstructured":"Kawakami A, Aikawa M, Alcaide P, Luscinskas FW, Libby P, Sacks FM. Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation. 2006;114(7):681\u20137.","journal-title":"Circulation"},{"issue":"4","key":"1080_CR54","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1093\/cvr\/cvv192","volume":"107","author":"H Li","year":"2015","unstructured":"Li H, Han Y, Qi R, Wang Y, Zhang X, Yu M, et al. Aggravated restenosis and atherogenesis in ApoCIII transgenic mice but lack of protection in ApoCIII knockouts: the effect of authentic triglyceride-rich lipoproteins with and without ApoCIII. Cardiovasc Res. 2015;107(4):579\u201389.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"1080_CR55","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12944-018-0867-5","volume":"17","author":"H Yingchun","year":"2018","unstructured":"Yingchun H, Yahong M, Jiangping W, Xiaokui H, Xiaohong H. Increased inflammation, endoplasmic reticulum stress and oxidative stress in endothelial and macrophage cells exacerbate atherosclerosis in ApoCIII transgenic mice. Lipids Health Dis. 2018;17(1):220.","journal-title":"Lipids Health Dis"},{"issue":"17","key":"1080_CR56","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1080\/15384101.2015.1064677","volume":"14","author":"L Juntti-Berggren","year":"2015","unstructured":"Juntti-Berggren L, Ali Y, Berggren PO. The pancreatic \u03b2-cell in deadly encounter with apolipoprotein CIII. Cell Cycle. 2015;14(17):2715\u20136.","journal-title":"Cell Cycle"},{"key":"1080_CR57","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1161\/ATVBAHA.115.305415","volume":"35","author":"A Qamar","year":"2015","unstructured":"Qamar A, Khetarpal SA, Khera AV, Qasim A, Rader DJ, Reilly MP. Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics. Arterioscler Thromb Vasc Biol. 2015;35:1880\u20138.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1080_CR58","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1172\/JCI200419992","volume":"114","author":"J Altomonte","year":"2004","unstructured":"Altomonte J, Cong L, Harbaran S, Richter A, Xu J, Meseck M, et al. Foxo1 mediates insulin action on apoC-III and triglyceride metabolism. J Clin Investig. 2004;114:1493\u2013503.","journal-title":"J Clin Investig"},{"key":"1080_CR59","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1161\/ATVBAHA.110.220723","volume":"31","author":"S Caron","year":"2011","unstructured":"Caron S, Verrijken A, Mertens I, Samanez CH, Mautino G, Haas JT, et al. Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia. Arterioscler Thromb Vasc Biol. 2011;31:513\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1080_CR60","doi-asserted-by":"crossref","unstructured":"\u2022 Sigfrids FJ, Stechemesser L, Dahlstr\u00f6m EH, Forsblom CM, Harjutsalo V, Weitgasser R, et al. Apolipoprotein C-III predicts cardiovascular events and mortality in individuals with type 1 diabetes and albuminuria. J Intern Med. 2022;291:338\u2013349. This study evaluated the role of apoC-III on diabetic kidney disease (DKD), cardiovascular outcomes, and mortality in type 1 diabetes.","DOI":"10.1111\/joim.13412"},{"issue":"8","key":"1080_CR61","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.2337\/dc16-0126","volume":"39","author":"A Digenio","year":"2016","unstructured":"Digenio A, Dunbar RL, Alexander VJ, Hompesch M, Morrow L, Lee RG, et al. Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes. Diabetes Care. 2016;39(8):1408\u201315.","journal-title":"Diabetes Care"},{"key":"1080_CR62","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12986-015-0058-6","volume":"12","author":"HF Raposo","year":"2015","unstructured":"Raposo HF, Paiva AA, Kato LS, de Oliveira HCF. Apolipoprotein CIII overexpression exacerbates diet-induced obesity due to adipose tissue higher exogenous lipid uptake and retention and lower lipolysis rates. Nutr Metab. 2015;12:61.","journal-title":"Nutr Metab"},{"key":"1080_CR63","doi-asserted-by":"crossref","unstructured":"Paiva AA, Raposo HF, Wanschel ACBA, Nardelli TR, Oliveira HCF. Apolipoprotein CIII overexpression-induced hypertriglyceridemia increases nonalcoholic fatty liver disease in association with inflammation and cell death. Oxid Med Cell Longev. 2017;1838679.","DOI":"10.1155\/2017\/1838679"},{"key":"1080_CR64","doi-asserted-by":"crossref","unstructured":"Valladolid-Acebes I, \u00c5vall K, Recio-L\u00f3pez P, Moruzzi N, Bryzgalova G, Bj\u00f6rnholm M, et al. Lowering apolipoprotein CIII protects against high-fat diet-induced metabolic derangements. Sci Adv. 2021;7(11):eabc2931.","DOI":"10.1126\/sciadv.abc2931"},{"key":"1080_CR65","doi-asserted-by":"publisher","first-page":"474","DOI":"10.3389\/fendo.2020.00474","volume":"11","author":"J Boren","year":"2020","unstructured":"Boren J, Packard CJ, Taskinen MR. The roles of ApoC-III on the metabolism of triglyceride-rich lipoproteins in humans. Front Endocrinol. 2020;11:474.","journal-title":"Front Endocrinol"},{"key":"1080_CR66","doi-asserted-by":"crossref","unstructured":"Recio-Lopez P, Valladolid-Acebes I, Berggren PO, Juntti-Berggren l. Apolipoprotein CIII reduction protects white adipose tissues against obesity-induced inflammation and insulin resistance in mice. Int J Mol Sci. 2022;23:62.","DOI":"10.3390\/ijms23010062"},{"issue":"11","key":"1080_CR67","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1210\/jc.2011-1159","volume":"96","author":"A Garg","year":"2011","unstructured":"Garg A. Lipodystrophies: genetic and acquired body fat disorders. J Clin Endocrinol Metab. 2011;96(11):3313\u201325.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1080_CR68","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1210\/jc.2015-3891","volume":"101","author":"A Kassai","year":"2016","unstructured":"Kassai A, Muniyappa R, Levenson AE, Walter MF, Abel BS, Ring M, et al. Effect of leptin administration on circulating apolipoprotein CIII levels in patients with lipodystrophy. J Clin Endocrinol Metab. 2016;101(4):1790\u20137.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1080_CR69","first-page":"315","volume":"119","author":"RK Semple","year":"2009","unstructured":"Semple RK, Sleigh A, Murgatroyd PR, Adams CA, Bluck L, Jackson S, et al. Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J Clin Invest. 2009;119(2):315\u201322.","journal-title":"J Clin Invest"},{"key":"1080_CR70","doi-asserted-by":"crossref","unstructured":"Lightbourne M, Wolska A, Abel BS, Rother KI, Walter M, Kushchayeva Y, et al. Apolipoprotein CIII and angiopoietin-like protein 8 are elevated in lipodystrophy and decrease after metreleptin. Endocr Soc. 2020;5(2):bvaa191.","DOI":"10.1210\/jendso\/bvaa191"},{"key":"1080_CR71","doi-asserted-by":"crossref","unstructured":"O\u2019Dea L, Tami J, Alexander V, Watts L, Hurh E, Hubbard B, et al. Oral Efficacy and safety of volanesorsen for the treatment of metabolic complications in patients with familial partial lipodystrophy: results of the BROADEN study. Endocrine Abstracts. 2020;70 OC3.7.","DOI":"10.1530\/endoabs.70.OC3.7"},{"key":"1080_CR72","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.RA120000919","volume":"62","author":"Y Hu","year":"2021","unstructured":"Hu Y, Meuret C, Martinez A, Yassine HN, Nedelkov D. Distinct patterns of apolipoprotein C-I, C-II, and C-III isoforms are associated with markers of Alzheimer\u2019s disease. J Lipid Res. 2021;62: 100014.","journal-title":"J Lipid Res"},{"key":"1080_CR73","first-page":"542","volume":"8","author":"HC Chan","year":"2020","unstructured":"Chan HC, Ke LY, Lu HT, Weng SF, Chan HC, Law SH, et al. An increased plasma level of ApoCIII-rich electronegative high-density lipoprotein may contribute to cognitive impairment in Alzheimer\u2019s disease. Biomedicine. 2020;8:542.","journal-title":"Biomedicine"},{"key":"1080_CR74","doi-asserted-by":"publisher","first-page":"855","DOI":"10.3233\/JAD-140111","volume":"41","author":"YH Shih","year":"2014","unstructured":"Shih YH, Tsai KJ, Lee CW, Shiesh SC, Chen WT, Pai MC, et al. Apolipoprotein C-III is an amyloid-\u03b2-binding protein and an early marker for Alzheimer\u2019s disease. J Alzheimer Dis. 2014;41:855\u201365.","journal-title":"J Alzheimer Dis"},{"key":"1080_CR75","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA120.015700","volume":"296","author":"F Schlotter","year":"2021","unstructured":"Schlotter F, de Freitas RCC, Rogers MA, Blaser MC, Wu PJ, Higashi H, et al. ApoC-III is a novel inducer of calcification in human aortic valves. J Biol Chem. 2021;296: 100193.","journal-title":"J Biol Chem"},{"key":"1080_CR76","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1161\/CIRCULATIONAHA.117.027776","volume":"135","author":"E Aikawa","year":"2017","unstructured":"Aikawa E, Libby P. A rock and a hard place: chiseling away at the multiple mechanisms of aortic stenosis. Circulation. 2017;135:1951\u20135.","journal-title":"Circulation"},{"key":"1080_CR77","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/MED.0000000000000136","volume":"22","author":"AB Kohan","year":"2015","unstructured":"Kohan AB. Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease. Curr Opin Endocrinol Diabetes Obes. 2015;22:119\u201325.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"1080_CR78","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1093\/eurheartj\/ehs271","volume":"34","author":"C Zheng","year":"2013","unstructured":"Zheng C, Azcutia V, Aikawa E, Figueiredo JL, Croce K, Sonoki H, et al. Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesion. Eur Heart J. 2013;34:615\u201324.","journal-title":"Eur Heart J"},{"key":"1080_CR79","doi-asserted-by":"publisher","first-page":"11087","DOI":"10.1096\/fj.202001062R","volume":"34","author":"JS Song","year":"2020","unstructured":"Song JS, Wang RS, Leopold JA, Loscalzo J. Network determinants of cardiovascular calcification and repositioned drug treatments. FASEB J. 2020;34:11087\u2013100.","journal-title":"FASEB J"},{"issue":"8","key":"1080_CR80","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11883-019-0791-9","volume":"21","author":"MR Taskinen","year":"2019","unstructured":"Taskinen MR, Packard CJ, Boren J. Emerging evidence that ApoC-III inhibitors provide novel options to reduce the residual CVD. Curr Atheroscler Rep. 2019;21(8):27.","journal-title":"Curr Atheroscler Rep"},{"issue":"9","key":"1080_CR81","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1038\/nm.4390","volume":"23","author":"SA Khetarpal","year":"2017","unstructured":"Khetarpal SA, Zeng X, Millar JS, Vitali C, Somasundara AVH, Zanoni P, et al. A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels. Nat Med. 2017;23(9):1086\u201394.","journal-title":"Nat Med"},{"issue":"5","key":"1080_CR82","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1056\/NEJMoa1400283","volume":"373","author":"D Gaudet","year":"2015","unstructured":"Gaudet D, Alexander VJ, Baker BF, Brisson D, Tremblay K, Singleton W, et al. Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N Engl J Med. 2015;373(5):438\u201347.","journal-title":"N Engl J Med"},{"key":"1080_CR83","doi-asserted-by":"crossref","unstructured":"\u2022 Witztum JL, Gaudet D, Freedman SD, Alexander VJ, Digenio A, Williams KR, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med. 2019;381(6):531\u201342. An important study showing that the inhibition of APOC3 mRNA decreased triglyceride levels to less than 750 mg per deciliter in 77% of patients with familial chylomicronemia syndrome.","DOI":"10.1056\/NEJMoa1715944"},{"issue":"33","key":"1080_CR84","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1093\/eurheartj\/ehz209","volume":"40","author":"VJ Alexander","year":"2019","unstructured":"Alexander VJ, Xia S, Hurh E, Hughes SG, O\u2019Dea L, Geary RS, et al. N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels. Eur Heart J. 2019;40(33):2785\u201396.","journal-title":"Eur Heart J"},{"issue":"33","key":"1080_CR85","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1093\/eurheartj\/ehz321","volume":"40","author":"A Qamar","year":"2019","unstructured":"Qamar A, Libby P, Bhatt DL. Targeting RNA to lower triglycerides: long strides from short molecules. Eur Heart J. 2019;40(33):2797\u2013800.","journal-title":"Eur Heart J"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-023-01080-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11883-023-01080-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-023-01080-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T22:06:20Z","timestamp":1677103580000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11883-023-01080-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,23]]},"references-count":85,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["1080"],"URL":"https:\/\/doi.org\/10.1007\/s11883-023-01080-8","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,23]]},"assertion":[{"value":"8 December 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Antonina Giammanco declares no competing interests. Rossella Spina declares no competing interests. Angelo Baldassare Cefal\u00f9 has received personal fees for consultancy or grant support from Amryt, Sanofi, and Sobi. Maurizio Averna has received research grant support from Sanofi and Amryt and has served as consultant for Sanofi, Amgen, Amryt, Akcea, Ionis, Alfasigma, and Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}